A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Dec 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CHT102 for patients with advanced pancreatic cancer that expresses a protein called mesothelin. The goal of the trial is to see how safe and effective this treatment is for patients whose standard treatments have not worked or who cannot tolerate them. The study is currently looking for participants who are between 18 and 70 years old and have been diagnosed with advanced pancreatic cancer. To qualify, patients must have a measurable tumor that shows mesothelin and are expected to live for at least 12 weeks.

If you or a loved one decides to participate, you will receive this new treatment and will be closely monitored by the research team throughout the process. This trial is important because it could lead to new options for patients who have limited treatments available. It’s essential for potential participants to understand the trial's purpose, eligibility requirements, and the commitment involved in taking part. If you're interested, please talk to your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Ability to understand and sign a written informed consent documen；
• • 2. At the date of signing ICF, 18 \~70 years old, male or female；
• • 3. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
• • 4. Positive mesothelin expression;
• • 5. At least one measurable lesion at baseline per RECIST version 1.1；
• • 6. The expected survival time is more than 12 weeks;
• • 7. ECOG 0-1 points;
• • 8. Adequate organ functions.